EyePoint, Inc. EYPT

EYPT Company Overview

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a U.S.-based biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company operates within the ophthalmology and biotechnology industries, with an emphasis on sustained-delivery drug technologies for chronic eye conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and non-proliferative diabetic retinopathy (NPDR). EyePoint’s primary value proposition centers on reducing treatment burden for patients and physicians through long-acting intraocular therapies.

The company’s core pipeline is led by DURAVYU (formerly EYP-1901), an investigational sustained-delivery intravitreal treatment that uses bioerodible Durasert technology to deliver vorolanib, a tyrosine kinase inhibitor. Historically, EyePoint also generated revenue through commercial ophthalmic products including YUTIQ and DEXYCU, though the company has increasingly shifted toward a clinical-stage biotechnology model focused on retinal therapeutics. EyePoint traces its origins to pSivida Corp., an ocular drug-delivery company founded in Australia in 2000; following corporate restructuring and strategic refocusing, the company adopted the EyePoint Pharmaceuticals name in 2018.